Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 3RE73 | — |
inadvertently administered dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a 2-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 3RE73, expiry date 16-NOV-2026) for prophylaxis. Co-suspect products included DTPa (Infanrix) for prophylaxis. On 12-JUN-2025, the patient received Boostrix. On an unknown date, the patient received Infanrix. On 12-JUN-2025, immediately after receiving Boostrix and not applicable after receiving Infanrix, the patient experienced wrong vaccine administered (Verbatim: inadvertently administered dose). The outcome of the wrong vaccine administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-JUN-2025 On 12 June 2025, a licensed practical nurse had called to report that she had inadvertently administered a dose of Boostrix to a 2-year-old patient instead of the scheduled dose of Infanrix earlier that same day, which led to wrong vaccine administered. She had asked how to proceed following the incorrect administration.